Study finds that lower dose of cannabidiol is as effective as higher dose in Dravet Syndrome.
A Phase 3 study presented at the American Academy of Neurology's Annual Meeting in Philadelphia has provided new evidence of the benefits of pharmaceutical-grade cannabidiol (Epidiolex) in treating Dravet Syndrome. Dravet Syndrome is an infantile onset developmental and epileptic encephalopathy associated with drug-resistant seizures.